Quality Assistance strengthens its scientific leadership with the launch of its Scientific Advisory Board (SAB)

At Quality Assistance, scientific excellence and innovation are at the heart of everything we do. We provide comprehensive analytical solutions to accelerate access to tomorrow’s life-changing therapies.

To reinforce this commitment, we have established a Scientific Advisory Board (SAB) composed of leading experts from the (bio)pharmaceutical industry and academia, alongside our internal scientific leaders.

The SAB strengthens our position as a highly skilled and trusted analytical partner in the development of innovative therapies, including biotherapeutics, peptides, oligonucleotides, mRNA-based therapies, viral vectors, cell and gene therapies, and vaccines.

By combining the diverse expertise, deep experience, and solution-driven mindset of its members, the SAB provides strategic guidance to ensure our scientific roadmap remains aligned with both our current and future challenges in drug development.

Mission of the SAB

The Scientific Advisory Board plays an essential role in ensuring our scientific and technological strategy aligns with the evolving needs of our clients and regulatory expectations. Its mission is to:

• Identify and prioritise emerging therapeutic modalities where Quality Assistance should invest to develop analytical capabilities, leveraging its scientific expertise to support pharmaceutical companies.
   
• Guide strategic investments in analytical techniques and technologies to anticipate future trends and accelerate innovation.

The SAB complements the daily work of our R&D and Innovation department, reinforcing the forward-looking approach already embedded in our organisation through continuous fit-and-gap analyses and proactive scientific assessments.

Members of the SAB